Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE ® FL-1 study evaluating fixed duration EPKINLY ® (epcoritamab-bysp) in combination with rituximab and ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE ® FL-1 study evaluating fixed duration EPKINLY ® (epcoritamab-bysp) in ...
Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2) resulted in statistically significant and clinically meaningful reduction in the risk of disease ...
SOUTH SAN FRANCISCO, Calif., December 08, 2025--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic ...
Claire Boyte-White is the lead writer for NapkinFinance.com, co-author of I Am Net Worthy, and an Investopedia contributor. Claire's expertise lies in corporate finance & accounting, mutual funds, ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE ® FL-1 study evaluating fixed duration EPKINLY ® (epcoritamab-bysp) in ...
SPRING, Texas, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today presentation at the San Antonio Breast ...
Steven Nickolas is a writer and has 10+ years of experience working as a consultant to retail and institutional investors. Charlene Rhinehart is a CPA , CFE, chair of an Illinois CPA Society committee ...
A mathematician has disclosed how he managed to win the lottery an astonishing 14 times. The 91-year-old utilised mathematical probability and calculated strategies to consistently claim jackpots over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback